Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males and females without compromised immune system~* Have a body mass Index of 18 to 32 kilograms per square meter (kg/m²)~Exclusion Criteria:~* Previously completed or withdrawn from an ixekizumab study or a study investigating interleukin-17 (IL-17) antagonists~* Have participated, within the last 30 days, in a clinical trial involving an investigational product. If the previous investigational product has a long half-life, 3 months or 5 half-lives (whichever is longer) should have passed~* Have known allergy or hypersensitivity to any biologic therapy~* Past vaccination allergy or Arthus-type hypersensitivity~* Received a tetanus toxoid-containing vaccine within the last 5 years~* Severe allergic reaction to Boostrix~* Allergic to latex~* Have been immunized with pneumococcal vaccine~* Known hypogammaglobulinemia~* History of Guillain-Barre Syndrome~* Active infectious disease~* Had a live vaccination within 1 year prior to screening, or intend to have a live vaccination during the course of the study~* Evidence of a significant uncontrolled neuropsychiatric disorder -~* Have a score of 3 on Item 12 of the Quick Inventory of Depressive Symptomatology-Self Report (16 Items) at screening~* Evidence of Human Immunodeficiency Virus infection, Hepatitis C, B~* Had symptomatic herpes zoster within 3 months of screening~* Women who are lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Ixekizumab + Boostrix® + Pneumovax®23 (Type: EXPERIMENTAL): Ixekizumab administered once by subcutaneous injection (SQ) at week 0 and once at week 2.~Boostrix® and Pneumovax®23 administered once by intramuscular (IM) injection into opposing arms at week 2.
- Boostrix® + Pneumovax®23 (Type: OTHER): Boostrix® and Pneumovax®23 administered once by IM injection into opposing arms at week 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).